Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472885 · ClinicalTrials.gov registry record · Phase 2
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03472885 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT03472885, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
To determine the effectiveness of ACH-0144471 (also known as danicopan and ALXN2040) in improving anemia when given with eculizumab for 24 weeks in participants with PNH. Danicopan dose may be increased within each participant, to a maximum of 200 milligrams (mg) three times daily (TID) based on safety and efficacy at protocol-specified time points.
Interventions
- DRUG Eculizumab
- DRUG Danicopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2023-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03472885
The ClinicalTrials.gov registry entry for NCT03472885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eculizumab is the first listed.
NCT03472885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03472885 about?
NCT03472885 is a clinical study titled "Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab". To determine the effectiveness of ACH-0144471 (also known as danicopan and ALXN2040) in improving anemia when given with eculizumab for 24 weeks in participants with PNH. Danicopan dose may be increased within each participant, to a maximum of 200 milligrams (mg) three times daily (TID) based on saf...
What is the current status of trial NCT03472885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-05-08. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT03472885?
The interventions under investigation include: Eculizumab (DRUG), Danicopan (DRUG).
Who is sponsoring clinical trial NCT03472885?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.